Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$0.48
$0.01(2.07%)
At close: 4:00 PM EDT
$0.48
$0.01(2.07%)
Day’s Range― - ―
52-Week Range$0.40 - $4.00
Previous CloseN/A
Volume40.38K
Average Volume (3M)415.73K
Market Cap
$24.05M
Enterprise Value$30.86
Total Cash (Recent Filing)$8.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding56,349,170
10 Day Avg. Volume347,176
30 Day Avg. Volume415,733
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside629.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$398.33K
Bulls Say, Bears Say
Bulls Say
Protected Technology PlatformA patented 3D ECG platform with multiple validated form factors gives HeartBeam a reusable technology base across post-discharge, ambulatory, and remote-care settings. This supports potential licensing and distribution expansion while creating intellectual-property protection around future product development.
Clinical And Regulatory ProgressRapid enrollment across cardiac studies and the FDA pre-submission mark meaningful de-risking of product validation and regulatory planning. Continued clinical execution could strengthen physician adoption, support a pivotal trial, and improve the company’s ability to commercialize its heart-attack detection platform.
Improving Cash EfficiencyLower quarterly operating cash use and management’s reduced full-year outflow target indicate improving spending discipline during commercialization. If maintained, greater efficiency can extend the available runway, preserve resources for clinical work, and reduce the pace at which additional financing is required.
Bears Say
No Revenue And Widening LossesThe absence of reported revenue alongside materially widening losses shows that HeartBeam has not yet converted product development into a self-funding business. Until commercial adoption produces recurring revenue, operating scale and profitability remain uncertain and depend on continued investment.
Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means HeartBeam continues consuming capital before reaching cash-flow breakeven. The announced equity program expands financing access but also confirms dependence on external funding, with future issuance potentially increasing dilution while commercialization develops.
Regulatory Approval Remains UncertainThe regulatory pathway for the heart-attack detection indication is not yet settled, so additional evidence, trial requirements, or conditions could extend timelines and increase development spending. This uncertainty delays broad commercialization and leaves the value of the platform dependent on future FDA feedback.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.40 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $24.05M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Aug 13, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.014.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.09.
How many shares outstanding does HeartBeam have?
HeartBeam has 56,349,170 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went down -15.28%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HeartBeam
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Company Deck
BEAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on clinical validation, strong IP protection, completed product development milestones, early commercial deployments, and improving cash efficiency — all meaningful positives. Key risks remain: commercial revenue is nascent, regulatory approval for the heart attack detection indication is pending (pre-submitted to FDA), cash balances require disciplined execution to reach profitability, and a leadership transition created near-term one-time costs. On balance, the highlights (clinical momentum, regulatory progress, IP strength, cost reductions and runway extension) outweigh the lowlights (early revenue, regulatory uncertainty, continued net losses), supporting a cautiously positive outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.50
▲(629.17% Upside)
Technical Analysis
Ownership Overview
16.84% Insiders
2.57% Mutual Funds
4.67% Other Institutional Investors
71.91% Public Companies and
Individual Investors